Schering-Plough Articles

Early development of six pharma agents urged in Japan

8 May 2006

S-P granted EU label change for Intron A

1 May 2006

US FTC report shows brand-name drug firms pay generics makers to stay off market

1 May 2006

Pyhtopharm presents quarterly update on pipeline developments

1 May 2006

Prophylaxis or treatment in coping with invasive fungal infections; EBMT meeting

1 May 2006

Bayer Yakuhin sees 2005 sales rise 4%

1 May 2006

Merck & Co sees 1st-qtr net income of $1.52B

1 May 2006

S-P starts recovery: 1st-qtr 2006 profit up 233%

1 May 2006

S-P completes enrollment in first stage of Ph II trial of HCV drug

24 April 2006

Schering-Plough promotes Raymond Russo

24 April 2006

S-P selects compound identified by Pharmacopeia

24 April 2006

Schering-Plough selects compound from Pharmacopeia accord

17 April 2006

S-P announces positive Avelox study data

17 April 2006

Codexis and Schering-Plough agree R&D accord

3 April 2006

US consortium set up to share drug test data and better understand safety

27 March 2006

Remicade approved as UC treatment

27 March 2006

S-P licenses PTC's HCV candidate portfolio

27 March 2006

GSK/S-P's Levitra 83% "effective" in patients on hypertension drugs

27 March 2006

Promotions and appointments at Schering-Plough

27 March 2006

Stock Commentary - New York week to Mar 20, 2006

27 March 2006

Gene Resnick joins new IT&E/Millennix combo

20 March 2006

Pharmacopeia's CXCR2 drug shows efficacy in Ph I

20 March 2006

Japan stock market week to Mar 13, 2006

20 March 2006

AstraZeneca's statin Crestor shows efficacy in new atherosclerosis study

20 March 2006

Vytorin reduces LDL-cholesterol by 52%

20 March 2006

S-P/Pharmacopeia's CXCR2 antagonist shows clinical activity in Ph I

20 March 2006

Senior international appointments at Schering-Plough

13 March 2006

Centocor/S-P's Remicade cleared for UC in EU

13 March 2006

Stock Commentary - New York week to Mar 6, 2006

13 March 2006

Bayer back on stream with EBIT up 56%, but antitrust costs hit and net falls 32%

13 March 2006

Japan recalculates eight drug ingredients due to high sales

27 February 2006

US FDA grants priority review to Schering-Plough's Noxafil

27 February 2006

Mixed data from S-P's vicriviroc in HIV study

20 February 2006

Stock Commentary - New York week to Feb 6

13 February 2006

S-P launches Noxafil in the UK for refractory IFI

13 February 2006

Review of 2nd International Workshop on HIV and Hepatitis Co-infection

13 February 2006

S-P's Temodol gets new indication in Canada

6 February 2006

Stock Commentary - New York week to Jan 30

6 February 2006

Merck & Co beats forecasts; profit up 2%

6 February 2006

CMHP issues positive opinion to S-P/Centocor's Remicade edging; closer to approval in the EU

6 February 2006

Schering-Plough's turnaround continues with 4th-qtr earnings at $104M

6 February 2006

Pharma/biotech mergers and acquisitions during 2005

6 February 2006

S-Ps Avelox outperforms Levaquin in CAP study

6 February 2006

Tripos enters new partnerships

30 January 2006

Statins account for 81% of first-line dyslipidemia treatment

30 January 2006

First EU biogenerics "possible in 2006, but USA faces long and winding road:" study

30 January 2006

Michael Boyd joins Schering-Plough as VP, public affairs, international

16 January 2006

Round-up of pharmaceutical mergers and acquisitions during 2001

9 January 2006

New indications in Japan for S-P drugs

9 January 2006

US FDA "failing to learn from mistakes" on risk communication, public meeting told

19 December 2005

S-P's new antibiotic performs well in trials

19 December 2005

Alder enters Ab R&D accord with S-P

12 December 2005

FDA OKs S-P/Bayer's Avelox for 6th indication

12 December 2005

SP's Claritin "clears your head," says study

5 December 2005

Schering-Plough appoints general managers for Poland and Philippines

19 September 2005

Schering-Plough's Nasonex "superior in scent and taste to GSK's Flonase"

12 September 2005

S-P to begin distribution of drug using CIMA's OraSolv

5 September 2005

S-P elects to develop RA drug with Centocor

22 August 2005

Bayer's Avelox approved for cSSSI in EU

15 August 2005

S-P licenses Sankyo's cardio drug in Latin territories

15 August 2005

Promotions at Schering-Plough

8 August 2005

Shorter dosing recommendations for S-P's PEG-Intron and Rebetol by CHMP

8 August 2005

NZ Pharmac gets budget boost, OKs new Rx uses

8 August 2005

PhRMA OKs DTC guide, to take effect Jan 2006

8 August 2005

Australian PBS adds 45 drugs, widens use for 28

8 August 2005

EMEA OKs Schering-Plough's Noxafil

8 August 2005

Stock Commentary - New York

1 August 2005

Schering-Plough recryutes John O'Mullane as VP, R&D, consumer health care

1 August 2005

S-P buys exclusive US rights to Integrilin

1 August 2005

Litigation reserves bite into Schering-Plough's 2nd-qtr, but sales rise 18%

1 August 2005

Stock Commentary - New York

18 July 2005

ViroLogic signs $4.8M deal with Schering-Plough

18 July 2005

Schering-Plough expands in Asia Pacific

18 July 2005

PegIntron/ribavirin 12-week therapy effective

4 July 2005

Does Japan change? - pharma executive mobility, restructuring by P Reed Maurer

4 July 2005

Miguel Ribas to head Schering-Plough's Puerto Rico unit

27 June 2005

S-P/Centocor's Remicade shows good results in PA

27 June 2005

EC clears S-P'sTemodal for new glioblastoma

20 June 2005

French CNMA warns over statin "misuse"

20 June 2005

Introgen wins over Schering-Plough on patent covering p53 therapeutics

13 June 2005

Schering-Plough promotes Michael Perelman to VP global project management at S-PRI

6 June 2005

NICE: S-P

30 May 2005

Japan stock market week to May 16

23 May 2005

Schering-Plough enters R&D collaboration with Southern Research Institute

16 May 2005

Schering-Plough promotes Jim Joyce to Ireland country manager

16 May 2005

Japan stock market week to May 9

16 May 2005

Israel's 2005 NHI drugs basket creates precedents for funding and registration

16 May 2005

Millennium's 1st-qtr losses narrow

9 May 2005

Schering-Plough creates "Biopharma" unit

9 May 2005

S-P names Theo Niewenhuis VP, Remicade marketing

9 May 2005

Biologics worth $11.2B to lose patents by 2010

9 May 2005

Clarification:

28 April 2005

Promotion at Schering-Plough in Ireland

28 April 2005

S-P/Merck & Co

27 April 2005

EU CHMP OK for S-P's Temodal for GBM

27 April 2005

Valeant's HCV drug gives good Phase II performance

26 April 2005

Stock Commentary - New York

25 April 2005

Urban Widen named general manager, Schering-Plough Sweden

25 April 2005

PegIntron/Rebetol in HCV: positive data

25 April 2005

Vioxx loss drags on Merck & Co results

22 April 2005

Showing 501-600 of 2053 articles

Go to beginningPreviousNextGo to end